SINGAPORE (June 1): Singapore eDevelopment (SeD) announced on Monday that its wholly-owned subsidiary Impact Biomedical’s suite of antiviral and medical technologies, which is co-owned by its scientific research partner, Global Research and Discovery Group Sciences (GRDG Sciences), is valued at $1.97 billion.
The valuation was conducted by independent experts who specialise in assessing the potential deal value of medical intellectual property.
Impact Biomedical’s ownership in the suite is estimated to be at $1.32 billion.
Impact Biomedical previously announced on April 23, that the suite was valued at $841 mil by strategic consultancy firm, Destum Partners.
Singapore eDevelopment says the new valuation is said to take into consideration the additional disease applications of the suite. As at the time of valuation, the scope of the suite includes: 3F Mosquito and Antiviral Biofragrance; Equivir, an OTC medication with broad antiviral activity; Laetose, a reduced calorie and low glycemic advanced sugar replacement; and Linebacker, a broad-spectrum universal therapeutic medication.
3F Mosquito and Antiviral Biofragrance is designed to protect large numbers of people in public areas from mosquitoes and viruses such as E. coli, MRSA, and COVID-19. Equivir is a patented medication that is used to treat against multiple types of influenza such as Cholera, Ebola, and COVID-19. Laetose, a sugar replacement, was created to address metabolic disorders and conditions such as obesity and diabetes. Linebacker is a patented therapeutic medication that is said to be effective against diseases such as Parkinson’s, various types of cancer, and pathogens including E. coli, cholera, influenza, SARS, MERS, malaria, and COVID-19.
Singapore eDevelopment shares closed flat at 5.5 cents on Friday prior to the announcement.
